Evaluation of Vildagliptin (Galvus) as add-on to Insulin in Residual beta-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.

Trial Profile

Evaluation of Vildagliptin (Galvus) as add-on to Insulin in Residual beta-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Vildagliptin (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 May 2014 Planned end date changed from 1 Aug 2014 to 1 Mar 2017 as reported by ClinicalTrials.gov.
    • 13 May 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top